Electra Therapeutics Inc is a late clinical-stage biopharmaceutical company focused on pioneering a new class of precision medicines for the treatment of immune-mediated diseases and cancer. The company's pipeline includes Ipsoprubart and ELA822.
Last trade$8.53
Day change+$0.22 (+2.65%)
Day range$8.07 – $9.40
Volume235,077
Market cap$522M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for ETRA.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ETRA, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Revenue
$0
Cost of revenue
$0
Gross profit
$0
Selling, general and administrative
$7.79M
Research and development
$17.27M
Total operating expenses
$25.06M
Operating income
-$25.06M
Interest expense
$0
Income before taxes
-$23.93M
Income taxes
$0
Net income
-$23.93M
Net income attributable to common shareholders
-$23.93M
EBITDA
-$25.06M
Basic earnings per share
-$3.47
Diluted earnings per share
-$3.47
Recent news
Company coverage with links to the original publishers.
Electra Therapeutics is pricing 21.7 million shares at $14-$16 each on Nasdaq under ticker ETRA, targeting up to $347 million to advance ipsoprubart through its SURPASS registration trial for secondary haemophagocytic lymphohistiocytosis. The offering values the clinical-stage antibody developer near $1 billion, with frontline data showing 100% overall survival at eight weeks versus historical 20-30% mortality rates.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.